Diffusion tensor MRI assesses corticospinal tract damage in ALS

Ellis, Claire; Simmons, Andrew; Jones, Derek K.; Bland, J. M.; Dawson, Jill; Horsfield, Mark A.; Williams, Steven; Leigh, P. Nigel

doi:10.1212/wnl.53.5.1051

Cited by 366 publications

(323 citation statements)

References 44 publications

Supporting

Mentioning

276

Contrasting

Unclassified

Order By: Relevance

“…Unique imaging characteristics on magnetic resonance spectroscopy, functional magnetic resonance imaging, and 18 Ffludeoxyglucose positron emission tomography may aid in diagnosis [61][62][63][64]. Findings on diffusion tensor imaging also correlate with ALS phenotypes [59], disease severity scales, and disease duration [60].…”

Section: Retigabine: a Case Study For Innovative Als Clinical Trial Dmentioning

confidence: 99%

“…Modern imaging modalities such as diffusion tensor imaging [59,60], magnetic resonance spectroscopy [61,62], functional magnetic resonance imaging [63], and 18 Ffludeoxyglucose positron emission tomography [64,65] are emerging as potential biomarkers of disease progression. Unique imaging characteristics on magnetic resonance spectroscopy, functional magnetic resonance imaging, and 18 Ffludeoxyglucose positron emission tomography may aid in diagnosis [61][62][63][64].…”

Section: Retigabine: a Case Study For Innovative Als Clinical Trial Dmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

2015

View full text Add to dashboard Cite

The last 2 decades have seen a surge in the number of amyotrophic lateral sclerosis (ALS) clinical trials with the hope of finding successful treatments. Clinical trialists aim to repurpose existing drugs and test novel compounds to target potential ALS disease pathophysiology. Recent technological advancements have led to the discovery of new causative genetic agents and modes of delivering potential therapy, calling for increasingly sophisticated trial design. The standard ALS clinical trial design may be modified depending on study needs: type of therapy; route of therapy delivery; phase of therapy development; applicable subpopulation; market availability of therapy; and utility of telemedicine. Novel biomarkers of diagnostic, predictive, prognostic, and pharmacodynamic value are undergoing development and validation for use in clinical trials. Design modifications build on the traditional clinical trial design and may be employed in either the learning or confirming trial phase. Novel designs aim to minimize patient risk, study duration, and sample size, while improving efficiency and promoting statistical power to herald an exciting era for clinical research in ALS.

show abstract

Section: Retigabine: a Case Study For Innovative Als Clinical Trial Dmentioning

confidence: 99%

Section: Retigabine: a Case Study For Innovative Als Clinical Trial Dmentioning

confidence: 99%

Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

2015

View full text Add to dashboard Cite

show abstract

“…These applications employ both the directional anisotropy that can be measured by DTI 4,5 as well as removal of this anisotropy through the use of the tensor trace. [6][7][8] For example, DTI is presently being explored as a research tool to study brain development, 9,10 multiple sclerosis, 11,12 amyotrophic lateral sclerosis (ALS), 13 stroke, 14,15, schizophrenia 16,17 and reading disability, 18 while trace imaging has become an essential part of clinical acute stroke assessment. [19][20][21][22] As first shown by Basser et al, 4 the diffusion ellipsoid obtained from DTI can not only provide a quantitative orientation-independent measure of diffusion anisotropy, 23,24 but also the predominant direction of water diffusion in image voxels.…”

Section: Introductionmentioning

confidence: 99%

Fiber tracking: principles and strategies – a technical review

2002

View full text Add to dashboard Cite

The state of the art of reconstruction of the axonal tracts in the central nervous system (CNS) using diffusion tensor imaging (DTI) is reviewed. This relatively new technique has generated much enthusiasm and high expectations because it presently is the only approach available to non-invasively study the three-dimensional architecture of white matter tracts. While there is no doubt that DTI fiber tracking is providing exciting new opportunities to study CNS anatomy, it is very important to understand its limitations. In this review we therefore assess the basic principles and the assumptions that need to be made for each step of the study, including both data acquisition and the elaborate fiber reconstruction algorithms. Special attention is paid to situations where complications may arise, and possible solutions are reviewed. Validation issues and potential future directions and improvements are also discussed.

show abstract

“…The most common finding is a reduction of FA in the CST, which is thought to be due to the neuronal degeneration of UMN. Increased MD along the CST has been reported by some investigators [9,12,45,46]; however, no such changes were observed in another study [10]. In one of these studies, Sage et al [45] spatially interpolated FA and MD over the course of CST.…”

Section: Clinical Applicationmentioning

confidence: 94%

“…In the search for the UMN markers, several neuroimaging modalities, especially diffusion tensor imaging (DTI) [8][9][10][11][12][13][14][15][16], proton magnetic resonance spectroscopy ( 1 H-MRS) [14,15,[17][18][19][20], perfusion imaging [21], magnetization transfer imaging [22] (MTI) and functional magnetic resonance imaging (fMRI) [23][24][25], have been used with varying success. This article presents an overview of these neuroimaging methods and their potential roles in ALS.…”

Section: Introductionmentioning

confidence: 99%

Neuroimaging in Amyotrophic Lateral Sclerosis

et al. 2011

View full text Add to dashboard Cite

Summary: Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by progressive degeneration of upper motor neurons (UMN) and lower motor neurons (LMN). While LMN dysfunction can be confirmed by electromyography (EMG) and muscle biopsy, UMN involvement is more difficult to detect, particularly in the early phase. Objective and sensitive measures of UMN dysfunction are needed for early diagnosis and monitoring of disease progression and therapeutic efficacy. Advanced magnetic resonance imaging (MRI) techniques, such as diffusion, perfusion, magnetization transfer imaging, functional MRI, and MR spectroscopy, provide insight into the pathophysiological processes of ALS and may have a role in the identification and monitoring of UMN pathology. This article provides an overview of these neuroimaging techniques and their potential roles in ALS.

show abstract

Diffusion tensor MRI assesses corticospinal tract damage in ALS

Abstract: The results support the use of diffusion tensor MRI in detecting pathology of the corticospinal tracts in ALS.

Cited by 366 publications

References 44 publications

Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Fiber tracking: principles and strategies – a technical review

Neuroimaging in Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About